Publication date: Sep 01, 2023
Managing SARS-CoV-2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab-cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. Real-life data in a heterogeneous cohort are few. The aim of this study is to evaluate the benefit of prophylaxis with tixagevimab-cilgavimab in a cohort of 202 patients affected by different hematological diseases (lymphoproliferative, myeloproliferative, autoimmune, patients recently receiving a bone marrow transplant), active (with ongoing treatment), or in watch-and-wait strategy, followed in our center, during a median follow-up of 249 (45-325) days. An incidence of 44 breakthrough infections (21. 8%) is reported, with no treatment-related adverse effects. Age ≥70 years, ongoing treatment (above all with monoclonal antibodies), baseline lymphoproliferative disorders, and prior virus exposure are identified as risk factors related to subsequent infection (p
| Concepts | Keywords |
|---|---|
| Antibodies | breakthrough infection |
| Bone | hematological diseases |
| Myeloproliferative | immunocompromised patients |
| Prior | prophylaxis |
| Transplant | SARS-CoV-2 |
| tixagevimab-cilgavimab |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | breakthrough infection |
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | hematological diseases |
| disease | VO | age |
| disease | MESH | lymphoproliferative disorders |
| disease | MESH | infection |
| disease | MESH | immunocompromised patients |